Key result
Novel TRFIA achieves ~0.89 correlation with commercial CLIA, enabling simultaneous cTnI detection for early AMI.
Why the study?
Existing methods measure total cTnI, but the clinical significance of undegraded full-size-cTnI levels is not well-understood.
Observational (n=85)
No
A novel dual-labeling TRFIA method can simultaneously detect cTnI-C complex and full-size-cTnI, potentially aiding in determining the duration of chest pain and continuous myocardial troponin release.
Answers are grounded in this paper and cite their sources.
May aid AMI timing assessment; leaves open whether dual detection improves outcomes over standard assays.
Background: The measurement of cardiac troponin I (cTnI) is widely used in the diagnosis of acute myocardial infarction (AMI). Although existing cTnI detection methods measure total cTnI, the significance of undegraded full-size-cTnI levels is still not well-understood. In this study, we have established a novel dual-labeling time-resolved fluorescence immunoassay (TRFIA) technique that simultaneously detects the cTnI-C complex and full-size-cTnI, allowing us to explore the clinical value of full-size-cTnI determination. Methods: An antibody against the 23–43 amino acid region of cTnI protected by endogenous cTnC is coupled to magnetic beads to provide a solid-phase antibody for capturing all cTnI. An antibody against cTnC in the cTnI-C complex labeled with Eu3+ was used to detect the cTnI-C complex, and an antibody labeled with Sm3+ near the C-terminal 190–203 amino acids of cTnI was used to detect full-size-cTnI. Through dual-labeling TRFIA, cTnI-C complex, full-size-cTnI, and the full-size-cTnI/cTnI-C ratio can be detected simultaneously. The dual-labeling TRFIA technique was used to analyze serum samples collected at different times during treatment and compare their full-size-cTnI/cTnI-C ratios. Results: The sensitivity for the cTnI-C-TRFIA complex was 0.02 ng/mL, the measurement range was 0.02–40 ng/mL, the average intra-batch coefficient of variation (CV) was 4.35%, and the inter-average CV was 6.23%. The correlation coefficient between cTnI-C-TRFIA and commercial cTnI-CLIA methods was R2 = 0.8887. The sensitivity for full-size-cTnI-TRFIA was 0.04 ng/mL, the measurement range was 0.04–40 ng/mL, the average intra-batch CV was 4.95%, and the average inter-batch CV was 7.79%. The correlation coefficient between full-size-cTnI-TRFIA and commercial cTnI-CLIA methods was R2 = 0.7247. Conclusions: Dual-labeling full-size-cTnI/cTnI-C-TRFIA analysis is helpful for determining the length of time of chest pain before admission and the degree of continuous release of cTnI in the myocardium. Thus, it is more for early prognosis than just detecting cTnI.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2021) conducted an observational in Acute Myocardial Infarction (n=85). Dual-labeling time-resolved fluorescence immunoassay (TRFIA) vs. Commercial cTnI-CLIA method was evaluated on Correlation coefficient between cTnI-C-TRFIA and commercial cTnI-CLIA methods (R2 = 0.8887). The novel dual-labeling TRFIA method demonstrated strong correlation with commercial CLIA methods and enables simultaneous detection of cTnI-C complex and full-size-cTnI for early AMI prognosis.
Synapse has enriched 10 related papers. Consider them for comparative context: